Case Report: Immunotherapy for low-grade myofibroblastic sarcoma of the pharynx.
immunotherapy
low-grade myofibroblastic sarcoma
pembrolizumab
pharynx
recurrence and multiple metastases
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
20
03
2023
accepted:
20
06
2023
medline:
21
7
2023
pubmed:
20
7
2023
entrez:
20
7
2023
Statut:
epublish
Résumé
Low-grade myofibroblastic sarcoma (LGMS) characterized by the increased proliferation of myofibroblasts is a rare type of malignant myofibroblastic tumor that frequently occurs in the head and neck region. Presently, there is no consensus regarding the treatment of LGMS. Here, we report a rare case of LGMS of the pharynx in a 40-year-old male admitted to our hospital. The patient underwent resection for a right metastatic lesion and parapharyngeal mass. However, he had recurrence and multiple metastases without a surgical indication. Then the patient received the treatment of anlotinib plus pembrolizumab for 4 cycles, and there was a partial response (PR) to the treatment. Due to the adverse reaction of anlotinib, the patient subsequently received monotherapy of pembrolizumab for 22 cycles and achieved a complete response (CR). As the first case report of the immunotherapy for LGMS, our study highlights that this strategy may be of great significance to the treatment of LGMS.
Identifiants
pubmed: 37469511
doi: 10.3389/fimmu.2023.1190210
pmc: PMC10352614
doi:
Types de publication
Case Reports
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1190210Informations de copyright
Copyright © 2023 Sun, Luo, Liu, He, He and Liu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Clin Nucl Med. 2020 Jul;45(7):549-551
pubmed: 32433178
Front Immunol. 2022 May 06;13:832593
pubmed: 35603147
Lancet Oncol. 2018 Mar;19(3):416-426
pubmed: 29370992
Oncol Lett. 2017 Jun;13(6):4307-4314
pubmed: 28588708
J Cancer Res Ther. 2018 Sep;14(Supplement):S796-S799
pubmed: 30249907
Am J Surg Pathol. 1998 Oct;22(10):1228-38
pubmed: 9777985
Oncologist. 2021 Oct;26(10):e1693-e1703
pubmed: 34105207
J Hematol Oncol. 2016 Oct 4;9(1):105
pubmed: 27716285
BMJ Case Rep. 2010 Nov 23;2010:
pubmed: 22797208
Virchows Arch. 2013 Dec;463(6):827-36
pubmed: 24132324
Cancer Med. 2022 Jun;11(11):2271-2283
pubmed: 35191609
J Pediatr Hematol Oncol. 2004 Feb;26(2):119-20
pubmed: 14767203
Cancer Manag Res. 2021 Mar 18;13:2595-2601
pubmed: 33776477
J Cancer Res Ther. 2013 Apr-Jun;9(2):284-6
pubmed: 23771376
Clin Cancer Res. 2022 Aug 15;28(16):3473-3479
pubmed: 35675031
Front Immunol. 2018 May 03;9:978
pubmed: 29774034
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Oct;104(4):530-9
pubmed: 17142072
J Neurosurg Pediatr. 2010 Sep;6(3):286-90
pubmed: 20809714
Cancer. 2017 Sep 1;123(17):3291-3304
pubmed: 28463396
J Natl Compr Canc Netw. 2022 Jul;20(7):815-833
pubmed: 35830886
Ear Nose Throat J. 2020 Aug;99(7):NP82-NP83
pubmed: 31138030
Clin Cancer Res. 2022 Dec 15;28(24):5290-5296
pubmed: 36228149
Anticancer Res. 2011 Sep;31(9):2989-94
pubmed: 21868549
Am J Clin Pathol. 2009 May;131(5):701-9
pubmed: 19369631
Int J Oral Sci. 2012 Sep;4(3):170-3
pubmed: 22935748
BMC Musculoskelet Disord. 2020 Dec 10;21(1):836
pubmed: 33302922
Ann Thorac Surg. 2020 Dec;110(6):e469-e471
pubmed: 32505704